Stock Taper 
Prothena Corporation plc is a late-stage clinical biotech developing novel therapies for serious diseases like amyloidosis, Parkinson's, and Alzheimer's, with ongoing Phase I-III trials and collaborations with Roche and Bristol-Myers.
Prothena's most advanced clinical-stage asset, a humanized monoclonal antibody targeting alpha-synuclein, is in Phase 2b trials for Parkinson's disease, developed in collaboration with Roche.
In May 2025, Prothena announced that its Phase 3 AFFIRM-AL clinical trial of birtamimab for the treatment of AL amyloidosis did not meet its primary endpoint. Following this result, the company discontinued all development of birtamimab and, in June 2025, initiated a corporate restructuring that included a substantial reduction of its workforce by approximately 63% to reduce operating costs.
In a significant strategic pivot, Prothena initiated a corporate restructuring that included an approximate 63% reduction in its workforce. This decision followed the discontinuation of its birtamimab program after the Phase 3 AFFIRM-AL clinical trial failed to meet its primary endpoint, fundamentally altering the company's operational focus and cost structure.
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both CorMedix (CRMD) and Prothena (PRTA). But which of these two stocks offers value investors a better bang for their buck right now?
Overall rating: C
| PEER | PRICE | |
|---|---|---|
 BIIB | $219.29 | COMPARE |
 DNLI | $18.62 | COMPARE |
 CRVS | $10.33 | COMPARE |
 RIGL | $46.59 | COMPARE |
 OLMA | $8.00 | COMPARE |
 VSTM | $7.78 | COMPARE |
 FDMT | $12.77 | COMPARE |
 ANNX | $3.99 | COMPARE |
